MedPath

Tramadol

Generic Name
Tramadol
Brand Names
Conzip, Durela, Qdolo, Ralivia, Ryzolt, Seglentis, Tridural, Ultracet, Ultram, Zytram
Drug Type
Small Molecule
Chemical Formula
C16H25NO2
CAS Number
27203-92-5
Unique Ingredient Identifier
39J1LGJ30J

Overview

Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of morphine. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as duloxetine and venlafaxine. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain. Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators. Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain. Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death. However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.

Indication

Tramadol is approved for the management of moderate to severe pain in adults. Tramadol is also used off-label in the treatment of premature ejaculation.

Associated Conditions

  • Acute Pain
  • Premature Ejaculation
  • Severe Pain
  • Acute, moderate, severe Pain
  • Moderate Pain

Research Report

Published: Jul 21, 2025

A Comprehensive Monograph on Tramadol (DrugBank ID: DB00193): Pharmacology, Clinical Use, and Safety Profile

Executive Summary

Tramadol is a centrally-acting synthetic analgesic used for the management of moderate to moderately severe pain in adults. Identified by DrugBank ID DB00193 and CAS Number 27203-92-5, it is classified as a small molecule drug. Its clinical utility is derived from a unique, dual mechanism of action that distinguishes it from traditional opioid analgesics. Tramadol functions as a weak agonist at the µ-opioid receptor and simultaneously inhibits the reuptake of serotonin and norepinephrine (SNRI), thereby modulating both opioid-mediated and monoaminergic descending pain pathways. This multimodal activity contributes to its efficacy across a spectrum of pain conditions, including neuropathic and chronic pain, and positions it as a Step 2 option on the World Health Organization's pain ladder.

The drug is administered as a racemic mixture of its (+)- and (-)-enantiomers, which act synergistically. The (+)-enantiomer and its primary active metabolite, O-desmethyltramadol (M1), are responsible for the µ-opioid receptor agonism and serotonin reuptake inhibition, while the (-)-enantiomer primarily inhibits norepinephrine reuptake. The conversion of tramadol to the more potent M1 metabolite is critically dependent on the cytochrome P450 2D6 (CYP2D6) enzyme. Genetic polymorphisms in CYP2D6 lead to significant inter-individual variability in analgesic response and toxicity risk. "Ultra-rapid metabolizers" are at high risk for opioid toxicity, including life-threatening respiratory depression, a fact highlighted in a specific FDA Black Box Warning that has led to contraindications in pediatric populations.

Continue reading the full research report

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/08/07
Not Applicable
Recruiting
National Cancer Institute, Egypt
2025/07/15
Not Applicable
Not yet recruiting
2025/06/29
Not Applicable
Completed
Syed Muhammad Abbas
2025/02/05
N/A
Recruiting
2024/12/19
Phase 4
Active, not recruiting
medina medical center
2024/12/11
Not Applicable
Not yet recruiting
2024/12/09
Phase 3
Recruiting
2024/09/25
Phase 4
Not yet recruiting
2024/09/19
Phase 4
Completed
Istanbul University - Cerrahpasa (IUC)
2024/08/20
Early Phase 1
ENROLLING_BY_INVITATION

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Aidarex Pharmaceuticals LLC
33261-483
ORAL
50 mg in 1 1
10/5/2012
Aidarex Pharmaceuticals LLC
33261-105
ORAL
50 mg in 1 1
10/22/2014
NuCare Pharmaceuticals,Inc.
68071-2648
ORAL
100 mg in 1 1
2/25/2022
Medsource Pharmaceuticals
45865-357
ORAL
50 mg in 1 1
7/19/2015
Medsource Pharmaceuticals
45865-170
ORAL
37.5 mg in 1 1
3/5/2024
Lupin Pharmaceuticals, Inc.
68180-697
ORAL
100 mg in 1 1
1/16/2024
Galephar Pharmaceutical Research Inc.
66277-239
ORAL
100 mg in 1 1
12/19/2022
Quality Care Products, LLC
55700-996
ORAL
100 mg in 1 1
2/24/2023
Sun Pharmaceutical Industries, Inc.
47335-860
ORAL
200 mg in 1 1
12/12/2023
Palmetto Pharmaceuticals, Inc.
68134-402
ORAL
5 mg in 1 mL
12/21/2023

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
SKUDEXA FILM-COATED TABLET 75 MG/25 MG
SIN15394P
TABLET, FILM COATED
75 mg
12/13/2017
PENGESIC CAPSULE 50 mg
SIN10512P
CAPSULE
50.00 mg
12/8/1998
ACUGESIC INJECTION 50 mg/ml (without preservative)
SIN10045P
INJECTION
50 mg/ml
9/23/1998
MABRON INJECTION 100 mg/2 ml
SIN08740P
INJECTION
100 mg/2 ml
6/6/1996
ULTRADOL F.C. TABLETS 37.5MG/325MG
SIN16498P
TABLET, FILM COATED
37.5mg
5/19/2022
TRADOL INJECTION 50 mg/ml
SIN10057P
INJECTION
50 mg/ml
9/23/1998
ACUGESIC CAPSULE 50 mg
SIN08953P
CAPSULE
50 mg
10/2/1996
TRAMADOL STADA INJECTION 100 mg/2 ml
SIN08367P
INJECTION
100 mg/2 ml
10/2/1995
TRACIDOL INJECTION 100mg/2ml
SIN15303P
INJECTION, SOLUTION
100mg
7/24/2017
TRAMADOL 50 STADA CAPSULE 50 mg
SIN08365P
CAPSULE
50 mg
10/2/1995

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
LUPIN-TRAMADOL/ACET
lupin pharma canada limited
02407981
Tablet - Oral
37.50 MG
N/A
PAT-TRAMADOL/ACET
02389274
Tablet - Oral
37.5 MG
8/14/2012
TRIDURAL
Endo Operations Ltd.
02296381
Tablet (Extended-Release) - Oral
100 MG
8/14/2007
TRAMADOL/ACET
sanis health inc
02426803
Tablet - Oral
37.5 MG
7/25/2014
TARO-TRAMADOL ER
02450445
Tablet (Extended-Release) - Oral
300 MG
5/27/2016
PRIVA-TRAMADOL/ACET
pharmapar inc
02391554
Tablet - Oral
37.5 MG
7/9/2013
MAR-TRAMADOL
marcan pharmaceuticals inc
02480859
Tablet - Oral
50 MG
7/18/2019
TRAMADOL-ACET
PRO DOC LIMITEE
02417502
Tablet - Oral
37.5 MG
2/3/2014
TRAMAPHEN-ODAN
odan laboratories ltd
02388294
Tablet - Oral
37.5 MG
9/5/2012
ZYTRAM XL
purdue pharma
02286440
Tablet (Extended-Release) - Oral
300 MG
12/7/2006

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.